Browsing Tag
BIOA
2 posts
Can longevity biotech finally go mainstream — or is BioAge’s $250m shelf another warning sign of investor fatigue?
BioAge Labs (NASDAQ: BIOA) files a $250M shelf to fund aging-drug programs. Can disciplined financing revive investor faith in longevity biotech?
From IPO to $250M shelf: Can BioAge Labs keep investor faith in the race for anti-aging drugs?
BioAge Labs (NASDAQ: BIOA) files $250M mixed securities shelf to fuel its aging drug pipeline. See what it means for investors today.